Drug firm Zydus Healthcare has launched a generic version of the anti-diabetic dapagliflozin tablets under the brand name Dapaglyn in India.
The tablets are made available at the strengths of 10 mg and 5 mg priced at Rs 17 and Rs 14, respectively, said the company in a statement.
Dapagliflozin is part of a newer class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. The once-daily tablets are indicated as an adjunct to diet and exercise, and aim to improve glycaemic control in adults with type 2 diabetes mellitus, Zydus Healthcare said.
“In keeping with its efforts to make therapies accessible and affordable to patients, the drug will be highly economical, priced at 1/3rd the cost than currently available dapagliflozin brands in India,” it added.